Metformin Sustained Release 850 Mg (Generic)

Product Overview

Metformin Sustained Release 850 mg is a prescription oral antihyperglycemic agent formulated for the management of type 2 diabetes mellitus. Produced by USV Pvt Ltd, this generic formulation delivers the active ingredient in a controlled‑release matrix that extends therapeutic activity over approximately 24 hours, allowing once‑daily administration. Each strip contains ten tablets, and the product is packaged in strengths of 850 mg per tablet. Available pack sizes include 100, 200, and 300 tablets, providing flexibility for patients and clinicians seeking consistent glycemic control.

What is Metformin Sustained Release 850 mg?

Metformin belongs to the biguanide class of antidiabetic drugs. The sustained‑release (SR) formulation differs from immediate‑release (IR) versions by employing specialized polymer coatings that slow drug dissolution, resulting in a gradual increase in plasma concentration and a flatter pharmacokinetic profile. This design reduces the peak plasma level, minimizes gastrointestinal irritation, and maintains steady hepatic glucose production suppression throughout the day. The 850 mg strength is the most commonly prescribed dose for patients who require a higher daily dose but wish to limit the number of tablets taken.

Uses and Benefits

The primary indication for Metformin Sustained Release 850 mg is the improvement of glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other oral agents or insulin. Clinical studies have demonstrated that SR therapy achieves comparable HbA1c reductions to IR formulations while producing fewer hypoglycemic episodes and less weight gain. Additional benefits include:

• Improved adherence due to once‑daily dosing.
• Reduced risk of lactic acidosis compared with higher‑dose immediate‑release regimens.
• Potential cardiovascular benefit, as observed in outcome trials.
• Weight‑neutral or modest weight loss effect.

These attributes make the SR product an attractive option for patients who experience gastrointestinal side effects with IR forms or who prefer a simplified dosing schedule.

How It Works

Metformin exerts its antidiabetic effect through multiple mechanisms:

1. Inhibition of hepatic gluconeogenesis, decreasing the liver’s production of glucose.
2. Enhancement of peripheral insulin sensitivity, increasing glucose uptake in muscle and adipose tissue.
3. Modest inhibition of intestinal absorption of glucose.
4. Activation of AMP‑activated protein kinase (AMPK), which regulates cellular energy metabolism.

In the sustained‑release formulation, the drug is released gradually, leading to a more stable plasma concentration that supports continuous AMPK activation and steady suppression of hepatic glucose output without the sharp peaks associated with immediate‑release dosing.

Dosage Guidelines

Typical dosing for Metformin Sustained Release 850 mg begins with one tablet taken once daily with the evening meal to minimize gastrointestinal discomfort. The dose may be titrated upward based on glycemic response, up to a maximum of 2,000 mg per day (often delivered as two 850 mg tablets). Dose adjustments are recommended in patients with renal impairment, liver disease, or conditions predisposing to hypoxia. Prior to initiation, baseline renal function should be assessed using an estimated glomerular filtration rate (eGFR); the drug is contraindicated when eGFR falls below 30 mL/min/1.73 m². Patients should be instructed to swallow the tablet whole and not crush or split it, as the SR coating is essential for the intended release profile.

For comprehensive prescribing information, refer to the FDA drug label or consult a healthcare professional.

Side Effects

Most patients tolerate Metformin Sustained Release well, but possible adverse effects include:

• Gastrointestinal disturbances such as nausea, abdominal discomfort, diarrhea, or metallic taste.
• Occasional vitamin B12 deficiency with long‑term use; periodic monitoring is advised.
• Rare but serious lactic acidosis, characterized by unexplained weakness, myalgia, rapid breathing, or dizziness; immediate medical attention is required. For more information, see the NIH’s page on lactic acidosis.
• Skin reactions such as rash or pruritus.

If any of these symptoms persist or worsen, patients should contact their physician promptly.

Warnings and Precautions

Before prescribing Metformin Sustained Release 850 mg, clinicians should review the patient’s medical history for:

• Renal or hepatic impairment.
• Congestive heart failure requiring aggressive diuretic therapy.
• Conditions that may precipitate hypoxia, such as acute respiratory infections.
• Concurrent use of imaging agents containing iodinated contrast, which may temporarily impair renal function.

Patients should be advised to suspend the medication prior to any surgical procedures or radiographic studies involving contrast dye. Alcohol consumption should be limited, as it increases the risk of lactic acidosis. Pregnant or lactating women should only use the drug under medical supervision, as safety data in these populations remain limited. For detailed kidney function guidance, see the NIH resource on renal dosing.

Frequently Asked Questions

1. Can Metformin Sustained Release be taken with food? Yes. The tablet should be taken with the evening meal to reduce gastrointestinal side effects and to support consistent drug absorption.
2. How long does it take to see a reduction in HbA1c? Most patients experience a measurable decline in HbA1c after 4–6 weeks of consistent therapy, with maximal effect typically observed after 12 weeks.
3. Is the SR formulation suitable for patients with kidney disease? It can be used in patients with mild to moderate renal impairment (eGFR 30–60 mL/min/1.73 m²) when titrated cautiously, but is contraindicated in severe impairment (eGFR <30). Always verify renal function before initiation.
4. What should I do if I miss a dose? If a dose is missed, it should be taken as soon as remembered unless it is near the time of the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed; double dosing is not recommended.
5. Are there any drug interactions I should be aware of? Metformin may interact with agents that affect renal function, certain contrast agents, and medications that increase the risk of lactic acidosis, such as cimetidine or excessive alcohol intake. Always review current medications with a healthcare provider.

Related Products

• Erytop Gel (Clindamycin)
• Okamet 500 Mg (Metformin)
• Angispan TR (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 2.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Angispan TR 6.5 mg (Nitroglycerin/Glyceryl Trinitrate)
• Glimepiride 2 mg (Generic)
• Glimepiride 1 mg (Generic)
• Glycomet-GP 0.5 Forte (Metformin/Glimepiride)
• Glycomet-GP 0.5 Tablet (Metformin/Glimepiride)
• Forxiga 5mg (Dapagliflozin)
• Glycomet-GP 1 Tablet (Metformin/Glimepiride)
• Amaryl M 1mg (Metformin/Glimepiride)